Translational Implications of Dysregulated Pathways and MicroRNA Regulation in Quadruple-Negative Breast Cancer

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 Feb 25

PMID 35203574

Authors

Amal Qattan

Taher Al-Tweigeri

Kausar Suleman

Affiliations

Soon will be listed here.

Abstract

Triple-negative breast cancers (HER2-, ER-, PR-) continue to present a unique treatment challenge and carry unfavorable prognoses. The elucidation of novel therapeutic targets has necessitated the re-evaluation of stratification approaches to best predict prognosis, treatment response and theranostic and prognostic markers. Androgen receptor expression and function have important implications on proliferation, tumor progression, immunity and molecular signaling in breast cancer. Accordingly, there has been increasing support for classification of androgen receptor-negative triple-negative breast cancer or quadruple-negative breast cancer (QNBC). QNBC has unique molecular, signaling and expression regulation profiles, particularly those affected by microRNA regulatory networks. microRNAs are now known to regulate AR-related targets and pathways that are dysregulated in QNBC, including immune checkpoint inhibitors (ICIs), SKP2, EN1, ACSL4 and EGFR. In this review, we explore and define the QNBC tumor subtype, its molecular and clinical distinctions from other subtypes, miRNA dysregulation and function in QNBC, and knowledge gaps in the field. Potential insights into clinical and translational implications of these dysregulated networks in QNBC are discussed.

Citing Articles

Analysis of single-cell and spatial transcriptomics in TNBC cell-cell interactions.

Xin Y, Ma Q, Deng Q, Wang T, Wang D, Wang G Front Immunol. 2025; 16:1521388.

PMID: 40079015 PMC: 11897037. DOI: 10.3389/fimmu.2025.1521388.

Androgen receptor expression and clinical significance in breast cancer.

Yao N, Han L, Sun H, Zhou L, Wei Z World J Surg Oncol. 2025; 23(1):48.

PMID: 39934842 PMC: 11816761. DOI: 10.1186/s12957-025-03673-w.

Advanced Insights into Competitive Endogenous RNAs (ceRNAs) Regulated Pathogenic Mechanisms in Metastatic Triple-Negative Breast Cancer (mTNBC).

Qattan A, Al-Tweigeri T, Suleman K, Alkhayal W, Tulbah A Cancers (Basel). 2024; 16(17).

PMID: 39272915 PMC: 11394539. DOI: 10.3390/cancers16173057.

Genomic Alterations Affecting Competitive Endogenous RNAs (ceRNAs) and Regulatory Networks (ceRNETs) with Clinical Implications in Triple-Negative Breast Cancer (TNBC).

Qattan A Int J Mol Sci. 2024; 25(5).

PMID: 38473871 PMC: 10931613. DOI: 10.3390/ijms25052624.

ACSL4: biomarker, mediator and target in quadruple negative breast cancer.

Monaco M Oncotarget. 2023; 14:563-575.

PMID: 37306503 PMC: 10259258. DOI: 10.18632/oncotarget.28453.

References

Sorolla A, Wang E, Clemons T, Evans C, Plani-Lam J, Golden E . Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine. 2019; 20:102003. DOI: 10.1016/j.nano.2019.04.006. View

Davis M, Tripathi S, Hughley R, He Q, Bae S, Karanam B . AR negative triple negative or "quadruple negative" breast cancers in African American women have an enriched basal and immune signature. PLoS One. 2018; 13(6):e0196909. PMC: 6005569. DOI: 10.1371/journal.pone.0196909. View

Bandini E, Fanini F . MicroRNAs and Androgen Receptor: Emerging Players in Breast Cancer. Front Genet. 2019; 10:203. PMC: 6433747. DOI: 10.3389/fgene.2019.00203. View

Shen Y, Yang F, Zhang W, Song W, Liu Y, Guan X . The Androgen Receptor Promotes Cellular Proliferation by Suppression of G-Protein Coupled Estrogen Receptor Signaling in Triple-Negative Breast Cancer. Cell Physiol Biochem. 2017; 43(5):2047-2061. DOI: 10.1159/000484187. View

Leung J, Sadar M . Non-Genomic Actions of the Androgen Receptor in Prostate Cancer. Front Endocrinol (Lausanne). 2017; 8:2. PMC: 5239799. DOI: 10.3389/fendo.2017.00002. View

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

Davey R, Grossmann M . Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016; 37(1):3-15. PMC: 4810760. View

Gelmann E . Molecular biology of the androgen receptor. J Clin Oncol. 2002; 20(13):3001-15. DOI: 10.1200/JCO.2002.10.018. View

Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M . Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers (Basel). 2014; 6(3):1351-62. PMC: 4190544. DOI: 10.3390/cancers6031351. View

10.

Shi P, Chen C, Li X, Wei Z, Liu Z, Liu Y . MicroRNA‑124 suppresses cell proliferation and invasion of triple negative breast cancer cells by targeting STAT3. Mol Med Rep. 2019; 19(5):3667-3675. PMC: 6472193. DOI: 10.3892/mmr.2019.10044. View

11.

Chintamani , Kulshreshtha P, Chakraborty A, Singh L, Mishra A, Bhatnagar D . Androgen receptor status predicts response to chemotherapy, not risk of breast cancer in Indian women. World J Surg Oncol. 2010; 8:64. PMC: 2922205. DOI: 10.1186/1477-7819-8-64. View

12.

Barton V, DAmato N, Gordon M, Christenson J, Elias A, Richer J . Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease. Horm Cancer. 2015; 6(5-6):206-13. PMC: 6897499. DOI: 10.1007/s12672-015-0232-3. View

13.

Rangel N, Rondon-Lagos M, Annaratone L, Aristizabal-Pachon A, Cassoni P, Sapino A . AR/ER Ratio Correlates with Expression of Proliferation Markers and with Distinct Subset of Breast Tumors. Cells. 2020; 9(4). PMC: 7226480. DOI: 10.3390/cells9041064. View

14.

Peluffo G, Subedee A, Harper N, Kingston N, Jovanovic B, Flores F . Is a Transcriptional Dependency in Triple-Negative Breast Cancer Associated with Brain Metastasis. Cancer Res. 2019; 79(16):4173-4183. PMC: 6698222. DOI: 10.1158/0008-5472.CAN-18-3264. View

15.

Qattan A . Novel miRNA Targets and Therapies in the Triple-Negative Breast Cancer Microenvironment: An Emerging Hope for a Challenging Disease. Int J Mol Sci. 2020; 21(23). PMC: 7727826. DOI: 10.3390/ijms21238905. View

16.

Brumec M, Sobocan M, Takac I, Arko D . Clinical Implications of Androgen-Positive Triple-Negative Breast Cancer. Cancers (Basel). 2021; 13(7). PMC: 8037213. DOI: 10.3390/cancers13071642. View

17.

Coussy F, Lavigne M, De Koning L, El Botty R, Nemati F, Naguez A . Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts. Theranostics. 2020; 10(4):1531-1543. PMC: 6993232. DOI: 10.7150/thno.36182. View

18.

Angajala A, Mothershed E, Davis M, Tripathi S, He Q, Bedi D . Quadruple Negative Breast Cancers (QNBC) Demonstrate Subtype Consistency among Primary and Recurrent or Metastatic Breast Cancer. Transl Oncol. 2018; 12(3):493-501. PMC: 6307536. DOI: 10.1016/j.tranon.2018.11.008. View

19.

Vera-Badillo F, Templeton A, de Gouveia P, Diaz-Padilla I, Bedard P, Al-Mubarak M . Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst. 2013; 106(1):djt319. DOI: 10.1093/jnci/djt319. View

20.

Cui W, Zhang S, Shan C, Zhou L, Zhou Z . microRNA-133a regulates the cell cycle and proliferation of breast cancer cells by targeting epidermal growth factor receptor through the EGFR/Akt signaling pathway. FEBS J. 2013; 280(16):3962-74. DOI: 10.1111/febs.12398. View